Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study

被引:27
|
作者
Clarkesmith, Danielle E. [1 ]
Lip, Gregory Y. H. [1 ,2 ]
Lane, Deirdre A. [1 ,2 ]
机构
[1] Univ Birmingham, Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Inst Cardiovasc Sci, Dudley Rd, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Patient education; Dabigatran; Warfarin; Anticoagulation; NET CLINICAL BENEFIT; STROKE PREVENTION; DECISION AID; OF-LIFE; ANTITHROMBOTIC THERAPY; MODELING ANALYSIS; DABIGATRAN; ADHERENCE; WARFARIN; POPULATION;
D O I
10.1016/j.thromres.2017.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Qualitative research on atrial fibrillation (AF) patient's experiences and perceptions of taking the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention is limited. This study explores patients' experiences of dabigatran and their recommendations for development of educational materials. Patients and methods: Semi-structured individual interviews with 8 warfarin-naive and 8 warfarin-experienced AF patients, using qualitative deductive thematic analysis. Results: The four main overarching themes included: understanding the diagnosis; reaching a treatment decision; challenges of living with OAC; and patient perceptions of treatment. Patients discussed their shock of diagnosis, and seeking information and support at that time. Narratives suggest patients preferred to be led by the doctor when making treatment decisions, and would often compare dabigatran to warfarin. Patients reported side-effects and challenges with both treatment options, and discussed their beliefs surrounding medications, including misconceptions. In addition to the original framework, two further themes were added: challenges of living with AF, and patient recommendations. Generally patients found AF symptoms distressing, which impacted their quality of life. Patient recommendations included the content and delivery of educational materials and development of tools to help with their understanding of AF and anticoagulation, as well as treatment adherence and anxiety surrounding symptoms and side effects. Conclusion: Patient recommendations emphasised the need for interventions to relieve anxiety surrounding the diagnosis and possible treatment side effects. Tailored 'disease-specific' support is essential to ensure efficacious treatment. This qualitative study highlights the need for patient involvement in the development of educational materials and resources for patients commencing treatment with NOACs. Crown Copyright (C) 2017 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 50 条
  • [31] Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
    Malagu, Michele
    Longo, Filomena
    Marchini, Federico
    Sirugo, Paolo
    Capanni, Andrea
    Clo, Stefano
    Mari, Elisa
    Culcasi, Martina
    Bertini, Matteo
    BIOLOGY-BASEL, 2023, 12 (04):
  • [32] Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
    Lip, Gregory Y. H.
    Wang, Kang-Ling
    Chiang, Chern-En
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 180 : 246 - 254
  • [33] Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
    Lee, So-Ryoung
    Lee, Young Soo
    Park, Ji-Suck
    Cha, Myung-Jin
    Kim, Tae-Hoon
    Park, Junbeom
    Park, Jin-Kyu
    Lee, Jung-Myung
    Kang, Ki-Woon
    Shim, Jaemin
    Uhm, Jae-Sun
    Kim, Jun
    Kim, Changsoo
    Kim, Jin-Bae
    Park, Hyung Wook
    Joung, Boyoung
    Choi, Eue-Keun
    YONSEI MEDICAL JOURNAL, 2019, 60 (03) : 277 - 284
  • [35] Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal
    Reddy, Sujan T.
    Cossey, T. C.
    Savitz, Sean I.
    Grotta, James C.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2017, 17 (09)
  • [36] Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Hu, Mu-Mei
    Wang, Jui
    Chien, Kuo-Liong
    Su, Chin-Ling
    Lin, Shin-Yi
    Wu, Fe-Lin Lin
    Lin, Zhen-Fang
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2017, 116 (04) : 276 - 286
  • [37] Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
    Li, Wenhao
    Zhou, Yanxia
    Chen, Siqi
    Zeng, Dewang
    Zhang, Haidong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [38] Safety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study
    Emren, Sadik Volkan
    Zoghi, Mehdi
    Berilgen, Rida
    Ozdemir, Ibrahim Halil
    Celik, Oguzhan
    Cetin, Nurullah
    Enhos, Asim
    Koseoglu, Cemal
    Akyuz, Abdurrahman
    Dogan, Volkan
    Levent, Fatih
    Dereli, Yuksel
    Dogan, Tolga
    Basaran, Ozcan
    Karaca, Ilgin
    Karaca, Ozkan
    Otlu, Yilmaz Omur
    Ozmen, Caglar
    Cosar, Selvi
    Sumerkan, Mutlu
    Gursul, Erdal
    Inci, Sinan
    Onrat, Ersel
    Ergene, Oktay
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2018, 18 (02) : 185 - 190
  • [39] Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin
    Huang, Huei-Kai
    Liu, Peter Pin-Sung
    Hsu, Jin-Yi
    Lin, Shu-Man
    Peng, Carol Chiung-Hui
    Wang, Jen-Hung
    Yeh, Jih-, I
    Loh, Ching-Hui
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (02):
  • [40] Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial
    De Caterina, Raffaele
    Camm, A. John
    EUROPACE, 2016, 18 (01): : 6 - 11